The protective effects of hepatocyte growth factor on the intestinal mucosal atrophy induced by total parenteral nutrition in a rat model

Sugita, Kenichiro; Kaji, Tatsuru; Yano, Keisuke; Matsukubo, Makoto; Nagano, Ayaka; Matsui, Mitsuaki; Murakami, Masakazu; Harumatsu, Toshio; Onishi, Shun; Yamada, Koji; Yamada, Waka; Muto, Mitsuru; Kumagai, Kotaro; Ido, Akio; Ieiri, Satoshi

doi:10.1007/s00383-021-05002-0

Cited by 5 publications

(2 citation statements)

References 31 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there was no significance in the absorptive mucosal area between the HGF treated mice compared to the TPN group. This could potentially stem from insufficient dose of HGF, which would require further research to investigate the optimal dosage [ 24 ]. Due to the attenuation of a few complications characterized by mucosal atrophy we can hypothesize that HGF may play a key role in mitigating gastrointestinal mucosal atrophy caused by TPN.…”

Section: Alterations Of Mechanical Signaling and Effects Of Tpn On Th...mentioning

confidence: 99%

Novel Therapeutic Approaches for Mitigating Complications in Short Bowel Syndrome

Bettag

Cunningham

et al. 2022

Nutrients

View full text Add to dashboard Cite

Short bowel syndrome (SBS) is a particularly serious condition in which the small intestine does not absorb sufficient nutrients for biological needs, resulting in severe illness and potentially death if not treated. Given the important role of the gut in many signaling cascades throughout the body, SBS results in disruption of many pathways and imbalances in various hormones. Due to the inability to meet sufficient nutritional needs, an intravenous form of nutrition, total parental nutrition (TPN), is administered. However, TPN presents difficulties such as severe liver injury and altered signaling secondary to the continued lack of luminal contents. This manuscript aims to summarize relevant studies into the systemic effects of TPN on systems such as the gut–brain, gut-lung, and gut-liver axis, as well as present novel therapeutics currently under use or investigation as mitigation strategies for TPN induced injury.

show abstract

Section: Alterations Of Mechanical Signaling and Effects Of Tpn On Th...mentioning

confidence: 99%

Novel Therapeutic Approaches for Mitigating Complications in Short Bowel Syndrome

Bettag

Cunningham

et al. 2022

Nutrients

View full text Add to dashboard Cite

show abstract

“…Significant efforts have been made to improve or prevent TPN-associated intestinal mucosal atrophy. In this sense, the studies performed in animal models of gut mucosal atrophy reported that the use of different growth and stimulation factors, including the epithelial growth factor [ 162 ], glucagon-like-protein-2 [ 163 ], hepatocyte growth factor [ 164 ], ghrelin [ 165 ], glutamate [ 166 ], arginine [ 167 ] or PUFA emulsions [ 168 , 169 ], can improve intestinal development and its function, thus preventing TPN-associated intestinal mucosal atrophy. Interestingly, prebiotic-, probiotic- and postbiotic-based treatments have been recently used in order to achieve this purpose.…”

Section: Influence Of Gastrointestinal Diseases In Infants and Childr...mentioning

confidence: 99%

Impact of Total Parenteral Nutrition on Gut Microbiota in Pediatric Population Suffering Intestinal Disorders

et al. 2022

View full text Add to dashboard Cite

Parenteral nutrition (PN) is a life-saving therapy providing nutritional support in patients with digestive tract complications, particularly in preterm neonates due to their gut immaturity during the first postnatal weeks. Despite this, PN can also result in several gastrointestinal complications that are the cause or consequence of gut mucosal atrophy and gut microbiota dysbiosis, which may further aggravate gastrointestinal disorders. Consequently, the use of PN presents many unique challenges, notably in terms of the potential role of the gut microbiota on the functional and clinical outcomes associated with the long-term use of PN. In this review, we synthesize the current evidence on the effects of PN on gut microbiome in infants and children suffering from diverse gastrointestinal diseases, including necrotizing enterocolitis (NEC), short bowel syndrome (SBS) and subsequent intestinal failure, liver disease and inflammatory bowel disease (IBD). Moreover, we discuss the potential use of pre-, pro- and/or synbiotics as promising therapeutic strategies to reduce the risk of severe gastrointestinal disorders and mortality. The findings discussed here highlight the need for more well-designed studies, and harmonize the methods and its interpretation, which are critical to better understand the role of the gut microbiota in PN-related diseases and the development of efficient and personalized approaches based on pro- and/or prebiotics.

show abstract

The effect of hepatocyte growth factor on intestinal adaption in an experimental model of short bowel syndrome

et al. 2023

View full text Add to dashboard Cite

Nowadays, the standard therapy for patients with short bowel syndrome is parenteral nutrition (PN). Various growth factors have been tested in order to achieve weaning from prolonged PN administration.We evaluated the effect of hepatocyte growth factor (HGF) on structural intestinal adaptation and cell proliferation in a rat model of SBS. MethodsThirty Sprague-Dawley rats were divided into three groups; group A rats (sham) underwent bowel transection, group B rats underwent a 75% bowel resection and group C rats underwent the same procedure but were treated postoperatively with HGF. Histopathologic parameters of intestinal adaptation were determined, while a microarray and a rt-PCR analyses of ileal RNA was also performed. ResultsTreatment with HGF resulted in signi cant increase in body weight, while the jejunal and ileal villus height and crypt depth were increased in HGF rats (36%, P < 0.05 and 27%, P < 0.05 respectively). Enterocyte proliferation was also signi cantly increased in HGF rats (21% P < 0.05). Microarray and quantitative rt-PCR analyses showed that the genes hgfac, rac 1, cdc42 and akt 1 were more than two-fold up-regulated after HGF treatment. ConclusionHGF emerges as a growth factor that enhances intestinal adaptation. The future use of HGF may potentially reduce the requirement for PN in SBS patients.

show abstract

The protective effects of hepatocyte growth factor on the intestinal mucosal atrophy induced by total parenteral nutrition in a rat model

Cited by 5 publications

References 31 publications

Novel Therapeutic Approaches for Mitigating Complications in Short Bowel Syndrome

Novel Therapeutic Approaches for Mitigating Complications in Short Bowel Syndrome

Impact of Total Parenteral Nutrition on Gut Microbiota in Pediatric Population Suffering Intestinal Disorders

The effect of hepatocyte growth factor on intestinal adaption in an experimental model of short bowel syndrome

Contact Info

Product

Resources

About